- Home
- ADAP vs SWZ Comparison
ADAP vs SWZ Comparison
Compare ADAP & SWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- SWZ
- Stock Information
- Founded
- ADAP 2008
- SWZ 1986
- Country
- ADAP United Kingdom
- SWZ United States
- Employees
- ADAP N/A
- SWZ N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- SWZ Finance Companies
- Sector
- ADAP Health Care
- SWZ Finance
- Exchange
- ADAP Nasdaq
- SWZ Nasdaq
- Market Cap
- ADAP 75.5M
- SWZ 82.2M
- IPO Year
- ADAP 2015
- SWZ N/A
- Fundamental
- Price
- ADAP $0.28
- SWZ $6.32
- Analyst Decision
- ADAP Buy
- SWZ
- Analyst Count
- ADAP 6
- SWZ 0
- Target Price
- ADAP $1.52
- SWZ N/A
- AVG Volume (30 Days)
- ADAP 1.6M
- SWZ 14.2K
- Earning Date
- ADAP 05-13-2025
- SWZ 01-01-0001
- Dividend Yield
- ADAP N/A
- SWZ 6.59%
- EPS Growth
- ADAP N/A
- SWZ N/A
- EPS
- ADAP N/A
- SWZ N/A
- Revenue
- ADAP $179,639,000.00
- SWZ N/A
- Revenue This Year
- ADAP N/A
- SWZ N/A
- Revenue Next Year
- ADAP $52.49
- SWZ N/A
- P/E Ratio
- ADAP N/A
- SWZ N/A
- Revenue Growth
- ADAP 878.53
- SWZ N/A
- 52 Week Low
- ADAP $0.20
- SWZ $7.12
- 52 Week High
- ADAP $1.48
- SWZ $8.57
- Technical
- Relative Strength Index (RSI)
- ADAP 49.68
- SWZ 33.35
- Support Level
- ADAP $0.26
- SWZ $6.24
- Resistance Level
- ADAP $0.30
- SWZ $6.36
- Average True Range (ATR)
- ADAP 0.03
- SWZ 0.07
- MACD
- ADAP 0.00
- SWZ 0.08
- Stochastic Oscillator
- ADAP 54.53
- SWZ 42.86
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.